102940.KQ
Kolon Life Science Inc.
KOE · Basic Materials · Chemicals · KR
KRW 14,560.00
−0.95%Year over year
Reported trailing growth
- Revenue
- +17.1%
- EBITDA
- +841.2%
- EBIT
- +429.7%
- EPS
- +268.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +9.0%
- EBITDA
- +28.2%
- EBIT
- +77.6%
- Net income
- +126.7%
- EPS
- +120.4%
- Free cash flow
- -23.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026